A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine
NCT ID: NCT00109083
Last Updated: 2012-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
300 participants
INTERVENTIONAL
2002-03-31
2006-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RWJ-333369
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have between 3 and 12 migraine attacks per month, and no more than 15 headache days in total per month;
* Migraines must have first started before age 50.
Exclusion Criteria
* Failed 3 or more studies of effective migraine-preventing medications;
* Overuse of pain medications to treat migraines;
* Not willing to stop use of migraine-preventing medications;
* Significant serious concomitant diseases.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SK Life Science, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Johnson & Johnson Pharmaceutical R & D, L.L.C., Clinical Trial
Role: STUDY_DIRECTOR
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northport, Alabama, United States
Phoenix, Arizona, United States
Little Rock, Arkansas, United States
Berkeley, California, United States
Golden, Colorado, United States
Miami, Florida, United States
St. Petersburg, Florida, United States
Chicago, Illinois, United States
Baton Rouge, Louisiana, United States
Brockton, Massachusetts, United States
Springfield, Massachusetts, United States
Chaska, Minnesota, United States
Springfield, Missouri, United States
Greensboro, North Carolina, United States
Bismarck, North Dakota, United States
Cincinnati, Ohio, United States
Mogadore, Ohio, United States
Nashville, Tennessee, United States
Austin, Texas, United States
Houston, Texas, United States
Lake Jackson, Texas, United States
Richardson, Texas, United States
Alexandria, Virginia, United States
Olympia, Washington, United States
Middleton, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP; Study Group. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache. 2009 Feb;49(2):216-26. doi: 10.1111/j.1526-4610.2008.01326.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
333369-MIG-2001
Identifier Type: -
Identifier Source: org_study_id